Program
MTAA is proud to have the following sponsors and exhibitors at the MedTech Conference 2025.
Introduction
Warren Bingham is a prominent figure in the medical devices, biotechnology and digital health sectors, known for his leadership and innovative contributions. He is the Founder and Executive Chairman of MedTech International, Global Vice President of ARIA Research, Executive Chairman of OmnisOva, Chairman of Agscent, and MTAA Board member. With over 30 years of experience in the medical devices sector, Warren specializes in guiding organizations towards innovation and success, particularly in medical devices and biotechnologies, excelling in global strategic execution, commercialization, and board fulfillment. In addition to his professional endeavors, Warren is deeply committed to philanthropy and community engagement. He serves as an Ambassador for the Vinnies CEO Sleepout and Diabetes Australia, contributes as a member of the Springboard Enterprises LifeSciences Council, and coaches for the Cerebral Palsy Alliance’s Accelerator, Remarkable and Taronga HATCH accelerator. Warren actively participates in initiatives aimed at driving positive change and making a tangible difference in people’s lives. Among Warren’s notable contributions to the healthcare industry is his role in establishing the Australian subsidiary of Given Imaging Ltd in 2001. Under his leadership, Given Imaging pioneered PillCam® technology, revolutionizing the visualization of the GI tract with its ingestible pill-sized camera. Warren’s strategic initiatives also led to the successful inclusion of Capsule Endoscopy on Australia’s Medicare Benefits Scheme in 2004. During his tenure on the global management team from 2000, Given Imaging experienced exponential growth, evolving from a start-up to a multinational, publicly traded company with revenues surpassing $250 million by 2013. In February 2014, Covidien acquired Given Imaging for approximately $1 billion. Warren’s exceptional leadership and contributions have garnered widespread recognition over the years. He was a finalist in the 2016 Australian Institute of Management’s ‘Excellence in Leadership Awards’ and was acknowledged by AusBiotech in 2018 for his ‘Outstanding Contribution to AusMedtech’. In 2019, Warren was named an Adjunct Fellow at Macquarie University and received the prestigious Medical Technology Association of Australia (MTAA) Outstanding Achievement Award in 2021 for his remarkable contributions to industry development, patient outcomes, and leadership. Warren’s unwavering passion, dedication, and visionary leadership continue to inspire positive change, drive innovation, and leave a lasting impact on the world
Welcome to Country
Yvonne is an independent councillor and the first Aboriginal Councillor in the City of Sydney’s 180-year history. She was born and raised in inner Sydney but maintains strong ties to her Wiradjuri homelands of Cowra and the Riverina areas of New South Wales.
Yvonne was inspired to run for Council to ensure local government is representative, helping those who have traditionally been excluded find their voice and influence change. Her vision is for a green, vibrant and inclusive Sydney humming with opportunity for all.
In her first term, Yvonne has consistently advocated for meaningful consultation with the local community and for Council to be more responsive in addressing prominent issues and concerns. Among those, she has campaigned for greater representation of First Nations people in the public domain and for the development of more affordable and social housing to tackle the ongoing housing crisis.
Prior to her election to Council, Yvonne has held numerous senior positions in NSW Government, non-government and Aboriginal controlled organisations working across health, human services, childcare, child protection, housing, disability services and Aboriginal heritage. She has served as the elected Chair of the Metropolitan Local Aboriginal Land Council, Deputy Chair of the NSW Australia Day Council and as a Board member of Domestic Violence NSW and Redfern Jarjum College.
Yvonne follows in the footsteps of a proud tradition of activists and change-makers (including her great-aunt Mum Shirl and her uncle Paul Coe, a prominent Aboriginal rights campaigner). Her family were instrumental in establishing the Aboriginal Children’s Service, Aboriginal Medical Service and Aboriginal Legal Service in Redfern.
Yvonne was awarded the 2019 NSW Volunteer of the Year for the South Sydney Region and in 2022 was recognised as the NSW Aboriginal Woman of the Year and appointed a Member of the Order of Australia for her service to the Aboriginal community. She also recently published her debut novel, Sixty-Seven Days. The previously unpublished manuscript was shortlisted for the Queensland Literary Awards David Unaipon Award.
Welcome & Official Opening
Ian Burgess is the CEO of the Medical Technology Association of Australia. Ian is a long-term leader in the Australian healthcare space having previously held CEO positions at the Australian Dental Association, Ortho Group Pty Limited and Australian Orthopaedic Association Limited. Ian is also a member of the Australian Institute of Company Directors and a non-executive director of Red Nose Ltd and SIDS and Kids (ACT) Ltd.
Sharing his inspiring and incredible story of humanity while confronted by the inequalities faced when accessing healthcare, Dr Daniel Nour brought to life a concept of free healthcare to the streets of society’s most vulnerable people with Street Side Medics.
Street Side Medics is a not-for-profit, GP-led mobile medical service for people experiencing homelessness. Currently, it is supported by more than 600 volunteers and ten clinics across the state. They treat many communicable and non-communicable illnesses, deal with neglected medical needs, and detect conditions that would otherwise have gone unnoticed.
Working as a full-time doctor at Royal North Shore Hospital, Dr Nour identified a gap in accessing quality healthcare. At the age of 26, he led the first mobile medical clinic, bringing volunteer GPs, trainee doctors and allied health professionals to treat Sydney siders experiencing homelessness, some of whom may not have seen a doctor for a decade or longer.
Street Side Medics has changed the lives of thousands of patients in New South Wales since it started. Dr Daniel Nour’s selfless work in creating the homeless medical service was recognised in 2022 as The Young Australian of the Year and The New South Wales Young Australian of the Year.
This is an incredible Australian story on how one socially conscious doctor, driven by the inequalities in accessing quality healthcare, is making a difference in the lives of many Australians.
Founder of Street Side Medics & NSW Young Australian of the Year 2022.
Identifying a gap in the healthcare of vulnerable people in New South Wales, Dr Daniel Nour founded Street Side Medics in August 2020. It’s a not-for-profit, GP-led mobile medical service for people experiencing homelessness.
With 600 volunteers, and ten clinics across New South Wales, Street Side Medics has changed the lives of more than thousands of patients. It has treated many communicable and non-communicable illnesses, dealt with neglected medical needs, and detected conditions that would otherwise have gone unnoticed.
Despite working full time at Royal North Shore Hospital, Daniel has rarely missed a clinic across the sites since Street Side Medics launched. He volunteers his afternoons to ensure the clinics are run smoothly and patients are receiving the care they deserve.
With his leadership and social consciousness, Daniel is committed to making a real difference to the lives of many Australians. He’s also making significant improvements to society.
Daniel’s dedication to serving the community, his commitment to Street Side Medics while working full time at Royal North Shore Hospital and his efforts to not miss a clinic across the sites demonstrates his strong sense of responsibility and passion for providing healthcare to those in need.
He volunteers his afternoons to ensure the clinics are run smoothly and patients are receiving the care they deserve.
Tracey Duffy heads the Medical Devices and Product Quality Division at the Therapeutic Goods Administration (TGA). Her division is responsible for regulation of medical devices including software and AI when used for therapeutic purposes. She is the former chair of the International Medical Device Regulators Forum (IMDRF), current chair of the IMDRF Personalised Medical Devices Working Group and current Chair of the Medical Single Audit Program Regulatory Authority Council.
Mitch Burger is a senior public health sector leader with experience across federal, state, and local public health and government organisations; encompassing acute, primary, community, and virtual health service provision. He has recently joined Healthdirect Australia as Chief Insights Officer, responsible for data, reporting, analytics, privacy, data governance, research, & evaluation. Previous to this he was Director, Strategy, Architecture, Innovation and Research at Sydney Local Health District. He is an Adjunct Senior Lecturer in the Discipline of Biomedical Informatics and Digital Health at the University of Sydney, and has conducted research in the School of Population Health at UNSW Sydney on the safe and equitable implementation of artificial intelligence in public health. He holds a Masters in Public Health from UNSW Sydney, and BComm (Hons I) from USYD.
Minta Chen is currently the Head of Global Regulatory Affairs and Quality Assurance for Annalise.ai. Annalise.ai is a developer of AI powered diagnostic software tool used by 1 in 2 radiologists in Australia, and is available to more than 40 countries globally. Minta has more than 20 years experience in regulatory affairs and quality assurance in the medical device sector. Her passion is enabling innovations and technologies to improve patient care.
Stephanie Owen is Microsoft’s Australian Consulting Lead for Healthcare. Microsoft Consulting is a global team of architects, consultants and project managers that work exclusively with Microsoft’s strategic customers to implement production-grade solutions using Microsoft’s latest technologies.
Stephanie is part of Microsoft’s health industry team, having previously worked in Customer Success and Consulting Delivery Executive roles serving two of Microsoft’s top strategic health accounts. Prior to Microsoft, Stephanie has worked as a Health CIO and ICT executive, with exposure to public and private hospitals, aged care, medical research, pathology, and ambulance services. She is a Fellow of the Australasian Institute of Digital Health and a Certified Health Informatician. She actively contributes to digital health through contributing to the first-ever Australian digital health textbook, mentoring, and serving on industry advisory groups including the AI Working Group, Digital Health Advisory Group and Cyber Security Working Group of the MTAA.
A passionate Digital Health Quality and Regulatory professional, Yan has over 10 years of experience in the pharmaceutical and medical device industries, with a specialised focus on Software as a Medical Device. Yan’s extensive and diverse background includes roles in regulatory affairs, quality management, clinical research, and product development. With a proven track record of interacting with major regulatory bodies such as the TGA, FDA, and EU-notified bodies, Yan brings a comprehensive understanding of the regulatory landscape to MedTech projects.
Jasjit Baveja holds a diverse background in both engineering and regulatory affairs within the MedTech industry. After completing her Bachelor of Electrical Engineering and Master of Biomedical Engineering, as well as a Ph.D., all from the University of New South Wales (UNSW), she ventured into roles encompassing regulatory affairs at prominent MedTech companies such as ResMed, Johnson & Johnson Medical, and Boston Scientific.
With her extensive experience in regulatory affairs, Jasjit transitioned to a broader scope within the industry, assuming the role of Director, Regulatory and Industry Policy, at the Medical Technology Association of Australia (MTAA). In this capacity, she holds significant responsibilities in shaping policies concerning regulatory matters, clinical affairs, and procurement within the MedTech sector.
Jasjit is also deeply involved in academia, serving as a lecturer at both the University of Newcastle and UNSW. Her teaching focuses primarily on regulatory affairs, imparting her knowledge and expertise to the next generation of professionals in the field. Furthermore, Jasjit’s commitment to academia extends to her role on the Industrial Advisory Board of the Graduate School of Biomedical Engineering, where she provides strategic insights and guidance.
Bernadette holds a PhD in health outcomes research from the University of Sydney and is a Director within the Clinical Trials Policy Section at the Australian Government Department of Health and Aged Care. She is working with the Department to support the delivery of national clinical trials reforms on behalf of all jurisdictions via the Inter-Governmental Policy Reform Goup These reforms include but are not limited to: the development and implementation of the National Clinical Trials Governance Framework; the National One Stop Shop and the development of a national quality standard and accreditation scheme for human research ethics committees under the National Mutual Acceptance Scheme.
Deborah is currently the Australasian Executive Director of Business Development for Avania, a leading global MedTech CRO. Prior to this Deborah was the Managing Director and Founder of Five Corners, a boutique CRO which merged with Avania in 2018. Deborah trained as a registered nurse in the UK and has incorporated her skills to provide effective clinical trial execution and field clinical support for international and Australasian clients. She provides regulatory guidance and has been responsible for the successful reimbursement approval of a number of novel and innovative technologies through both MSAC and Prostheses Listing. She now combines her many years of experience in proving strategic guidance for clients on their journey of medical device development from inception to commercialisation and remains passionate about streamlining the regulatory and clinical processes to bring new technologies to patients. Deborah is the current chair of the MTAA Clinical Investigation Forum and attends the MTAA IPC on behalf of this group. Deborah also serves on the CTIQ Exec Committee.
Professor Andrea O’Connor, PhD, FIChemE is the Shanahan Chair in Frontier Medical Solutions and a Redmond Barry Distinguished Professor at the University of Melbourne and the Aikenhead Centre for Medical Discovery. She is a co-Director of the Victorian Medtech Skills and Device Hub and leads the Tissue Engineering Group in the Department of Biomedical Engineering. Her research focuses on design, synthesis and fabrication of biomaterials, porous materials and antimicrobial nanomaterials. She teaches biomedical engineering subjects including Tissue Engineering and Stem Cells. Prof. O’Connor collaborates with clinicians, scientists, hospitals, medical research institutes and medical device companies to address clinical problems.
Dr Bernadette Morris Smith: Principal Policy Officer, Australian Teletrials Program Bernadette has over 30 years of experience in clinical research, from global clinical trials within the pharmaceutical industry to the public health service. Originally trained as a pharmacist with a PhD in anti-infectives from the United Kingdom, Bernadette has worked with several major Contract Research Organisations as well as global sponsors. Bernadette has a particular interest in health equity and improving patient outcomes, and has been involved in Teletrials since their inception. She is passionate about helping the Australian Teletrial Program expand, and even works and travels to remote regions of Australia, including First Nations communities. Bernadette brings commercial business development experience and hands-on clinical trial experience to the Australian Teletrials Program team.
Dr Lisa Eckstein is the Director of Philanthropic Activities for Bellberry Ltd and the CT:IQ Programme Director. Her previous role was as a senior lecturer in the faculty of Law at the University of Tasmania, where she chaired the Tasmania Health and Medical Human Research Ethics Committee and published on the regulation of clinical trials, genomic privacy, and consent. Prior to academia, Lisa worked as a legal officer for the Australian Law Reform Commission and for state and federal health departments.
Deama Amr is a leader in clinical research, currently serving as the Director for Clinical Research and Medical Science at Medtronic Australasia. Her career began at the National Centre for HIV and Epidemiological Research, before moving to Abbott Australasia and the George Institute. Attracted by Medtronic’s mission, Deama joined as a Principal Clinical Research Specialist. She has since grown her team from two to 30, managing nearly 100 trials across ANZ during her tenure at Medtronic. Her leadership has established the region as a key hub for First in Human (FIH) studies for Medtronic, driven by her focus on talent development and streamlined processes and leveraging the strengths that ANZ have to offer to accelerate technology access to ANZ patients. Deama’s advocacy extends to government and industry, promoting efficient clinical trials. She chaired the Medtronic Women’s Network in ANZ (2015-2017), winning the Hub of the Year award, and champions diversity and equity at Medtronic. Holding a PhD in Pharmacology from the University of Sydney, Deama advises on several industry groups and celebrated her 10th anniversary at Medtronic this year. Her journey exemplifies visionary leadership, transforming clinical research and fostering a culture of excellence and inclusivity.
Manoj is a Partner in L.E.K.’s Melbourne office focusing primarily on the healthcare / life sciences sector. He has supported numerous multinational MedTech and pharma companies with growth strategy, launch strategy and commercial excellence projects as well as supported transactions involving healthcare services and medical device distribution.
Discussion about the current management of the Prescribed List, future reforms and what industry should know.
Andrew Rintoul is the Assistant Secretary of the Prescribed List Reform Taskforce at the Australian Government Department of Health and Aged Care. Andrew is a Health Economist and has worked in the health industry in government and intergovernmental roles for over 20 years, primarily working on access to Health Products and their affordability. Andrew has had a variety of roles, including pricing of pharmaceuticals, health technology assessment, and Australia’s COVID-19 vaccines rollout. Andrew worked for the World Health Organization in Geneva as a Scientist from 2017 – 2020 where his focus was on pricing of pharmaceuticals and establishing the WHO Fair Pricing Forum.
Kristy is Director of Health Economics and Market Access at Johnson and Johnson MedTech. She is currently Chair of the MTAA Reimbursement Committee. In this role she has been involved in shaping industry response and engagement on the PL reform workstreams. She is an experienced Market Access professional who has built an excellent knowledge of the Australian medical device sector working across various functions and therapeutic areas. She is motivated by work that helps give patients access to life improving technologies.
Professor Hugh McDermott began his research career in 1981 as a PhD student developing an innovative cochlear implant. That device was successfully implanted in three people with profound hearing loss, and techniques he developed during the project were subsequently incorporated into commercial cochlear implant systems manufactured by the Australian company Cochlear Ltd. He then expanded his research to improve sound-processing techniques for cochlear implants; the fundamental method he devised has remained the essential element of all speech processors used with Cochlear systems to this day. He continued his research in sound processing and developed an innovative technique to assist users of acoustic hearing instruments. This was also commercially successful; it has been incorporated into millions of hearing aids made by the world’s largest manufacturer of hearing devices. After his appointment as deputy director of the Bionics Institute, Prof McDermott established a project to advance deep brain stimulation, a therapy providing benefit to people living with Parkinson’s disease and other disorders. He is currently the Chief Scientific Officer of DBS Technologies Pty Ltd, a company created to commercialise innovations developed by his team.
Ludovic is a leader in his field with over 20 years’ of international experience in the medical device and advanced manufacturing sector. Ludovic has worked throughout Europe, the USA and Asia Pacific with global companies including Fortive, Danaher, Siemens, Tektronix and Invetech. Ludovic’s experience spans the entire advanced manufacturing value-chain with proven success in bringing innovations to market to generate profitable growth in global hi-tech and medical devices markets in roles ranging from product ideation to go-to-market strategy. As CEO of Neo-Bionica, he is focused on driving successful commercialisation within the MedTech sector through end-to-end manufacturing services to emerging, digitally-enabled, bionic and AI powered smart medical device innovators.
Peter Single graduated from The University of Sydney in 1979 with degrees in Science and Electrical Engineering. His first job was designing low-power integrated circuits for AWA Microelectronics. He worked for National Semiconductor in Santa Clara (USA) on an integrated modem. He then worked for Austek Microsystems where he was a designer of the speech processor chip used by Cochlear in their MSP and Spectra 22 speech processors, then going on to work for them for 13 years. During this period he worked on speech processors and implants becoming familiar with active implantable medical devices and neural recording.
Peter was a founding employee (and is now CTO) of Saluda, which has developed an implant for treatment of chronic neuropathic pain that records the response of the spinal cord to stimulation and adjusts its output accordingly. This device is now being sold in Europe, the USA and Australia.
Brett is an executive director at advisory firm Intrinsika, bringing around 30 years of commercial experience to Intrinsika’s clients, helping them to identify, de-risk and grow their intrinsic value. Independently recognised as a “Global Leader in IP Strategy” by IAM, Brett has spent the last 15 years specialising in commercialisation, valuation, and strategic consulting for start-ups, scale-ups, government-funded bodies, universities, and companies listed on the ASX, NASDAQ, and SGX. He has managed over 200 projects related to intangible and intrinsic asset strategy and company valuation across a range of sectors, including medtech, agtech, foodtech, fintech and software. His clients include the World Intellectual Property Organization (WIPO), MTPConnect, Aegros, Artrya, Metabolic Health Solutions, Eudaemon, Zespri, Treasury Wines, Rhino-Rack, SATS (Singapore) and Johor Corporation (Malaysia). Brett’s commercial experience includes being Vice President in the life sciences team at a $1B US private equity fund, where he managed a $4M investment in a novel orthopaedic device, among other projects. Brett is also a registered Australian and New Zealand patent and trade marks attorney with a decade of experience in both in-house and private practice roles in Australia and the UK, including serving as IP Manager at former ASX-listed medtech company Ventracor Ltd.
Yan Lin has spent her career building deep tech businesses in Europe, APAC and US. Her most recent stint was with Cambridge Consultants where she built their APAC Medtech practice from the ground up. Her focus is medtech and the commercialization of technology. She has worked with and mentored 100+ start ups in addition to doing technology strategy for large multinationals.
AI, deep brain stimulation, Augmented Reality and other groundbreaking digital technologies, and the skills required to revolutionise the future of healthcare. How can the multiple stakeholders in the healthcare ecosystem collaborate for improved patient access to care?
Warren Bingham is a prominent figure in the medical devices, biotechnology and digital health sectors, known for his leadership and innovative contributions. He is the Founder and Executive Chairman of MedTech International, Global Vice President of ARIA Research, Executive Chairman of OmnisOva, Chairman of Agscent, and MTAA Board member. With over 30 years of experience in the medical devices sector, Warren specializes in guiding organizations towards innovation and success, particularly in medical devices and biotechnologies, excelling in global strategic execution, commercialization, and board fulfillment. In addition to his professional endeavors, Warren is deeply committed to philanthropy and community engagement. He serves as an Ambassador for the Vinnies CEO Sleepout and Diabetes Australia, contributes as a member of the Springboard Enterprises LifeSciences Council, and coaches for the Cerebral Palsy Alliance’s Accelerator, Remarkable and Taronga HATCH accelerator. Warren actively participates in initiatives aimed at driving positive change and making a tangible difference in people’s lives. Among Warren’s notable contributions to the healthcare industry is his role in establishing the Australian subsidiary of Given Imaging Ltd in 2001. Under his leadership, Given Imaging pioneered PillCam® technology, revolutionizing the visualization of the GI tract with its ingestible pill-sized camera. Warren’s strategic initiatives also led to the successful inclusion of Capsule Endoscopy on Australia’s Medicare Benefits Scheme in 2004. During his tenure on the global management team from 2000, Given Imaging experienced exponential growth, evolving from a start-up to a multinational, publicly traded company with revenues surpassing $250 million by 2013. In February 2014, Covidien acquired Given Imaging for approximately $1 billion. Warren’s exceptional leadership and contributions have garnered widespread recognition over the years. He was a finalist in the 2016 Australian Institute of Management’s ‘Excellence in Leadership Awards’ and was acknowledged by AusBiotech in 2018 for his ‘Outstanding Contribution to AusMedtech’. In 2019, Warren was named an Adjunct Fellow at Macquarie University and received the prestigious Medical Technology Association of Australia (MTAA) Outstanding Achievement Award in 2021 for his remarkable contributions to industry development, patient outcomes, and leadership. Warren’s unwavering passion, dedication, and visionary leadership continue to inspire positive change, drive innovation, and leave a lasting impact on the world
Professor Hugh McDermott began his research career in 1981 as a PhD student developing an innovative cochlear implant. That device was successfully implanted in three people with profound hearing loss, and techniques he developed during the project were subsequently incorporated into commercial cochlear implant systems manufactured by the Australian company Cochlear Ltd. He then expanded his research to improve sound-processing techniques for cochlear implants; the fundamental method he devised has remained the essential element of all speech processors used with Cochlear systems to this day. He continued his research in sound processing and developed an innovative technique to assist users of acoustic hearing instruments. This was also commercially successful; it has been incorporated into millions of hearing aids made by the world’s largest manufacturer of hearing devices. After his appointment as deputy director of the Bionics Institute, Prof McDermott established a project to advance deep brain stimulation, a therapy providing benefit to people living with Parkinson’s disease and other disorders. He is currently the Chief Scientific Officer of DBS Technologies Pty Ltd, a company created to commercialise innovations developed by his team.
Andrew’s Career in Healthcare spans 38 years. In his current role with Amazon Web Services, Andrew has responsibility for Healthcare Public Policy, supporting AWS public policy teams across the APAC region Previously Andrew led the Health Economics, Market Access, Policy and Government and Stakeholder Relations functions for Medtronic in Australia and New Zealand, in addition to coordinating Government Affairs for the APAC region. Over the span of his career Andrew has had a variety of roles within the Medtech Industry, across business and functional leadership. Andrew originally trained as a Registered Nurse and has worked in the Pharmaceutical Industry as well as a brief stint in the Hospitality Industry. He holds a MBA from the University of New England and a BA in Media from Griffith University. Andrew is a Board member of ARCS Australia and Hearts4Heart and has previously held several Directorships including of the Medical Technology Association of Australia (MTAA), He is a Graduate Member of the Australian Institute of Company Directors (GAICD) and a previous Governor of the American Chamber of Commerce in Australia (AmCham) and a founding member of the AmCham Australia Health Committee, and is Chair of the MTAA Digital Health Advisory Group and an active member of the APACMed Health Data group.
Geoff Quattromani is the Head of Technology for J&J MedTech and has been with the company in various roles for over 15 years. Geoff serves as the co-chair for the MTAA Digital Health Advisory Group and sits on the MTAA Cybersecurity Working Group.
The evidence requirements published in the draft Prescribed List Guide in December 2023 set a high bar even for devices that are only seeking to list in the same group and the same benefit on the PL. The industry is concerned that the requirements are very difficult to meet and are much higher hurdles that in comparable overseas jurisdictions. What drives the requests by ECAGs and MDHTAC for these evidence requirements? What risks are they trying to mitigate? How do they fit with the efficacy and safety assessments of the TGA? This session will discuss these issues and more with chairs of key committees and the Department.
Terry was Professor of Medicine at St Vincent’s Hospital, Sydney from 1998-2017, and was Deputy Dean of Medicine at UNSW (2006-17). He is a clinical cardiologist who trained in Internal Medicine and Cardiology at St Vincent’s Hospital and in Pharmacology at Oxford University. His own research has encompassed both basic laboratory research in cardiac pharmacology and clinical cardiology, and he has published over 120 peer-reviewed papers in these fields. His work has been cited over 5000 times. He is a Past President of the Cardiac Society of Australia and New Zealand (2000-2), past Deputy Chair of the National Heart Foundation (NSW), and past Chair of the Therapeutics Advisory Committee of the Royal Australian College of Physicians (1996-2000). He served 15 years on the Pharmaceutical Benefits Advisory Committee (2001-16) and since 2016, has been Chair of the Medical Devices and Human Tissue Advisory Committee within the Australian Department of Health.
Associate Professor Peter Lewis is an Orthopaedic Surgeon from Adelaide who chairs the Hip and Knee Expert Clinical Advisory Group, and is also a member of the Medical Device and Human Tissue Advisory Committee for the Department of Health and Aged Care. He was previously a member (from 2009) and then chair (from 2015) of the Knee Prosthesis Clinical Advisory Group. In addition to private and public practices, for the last 11 years Peter has been a Deputy Clinical Director of the Australian Orthopaedic Association National Joint Replacement Registry.
Professor Tony Lawler is Deputy Secretary of the Health Products Regulation Group and Chief Medical Officer with the Australian Government Department of Health and Aged Care.
The Health Products Regulation Group works to safeguard and enhance the health of all Australians through effective, timely and risk-proportionate regulation of therapeutic goods, and the control of drug imports, exports and production. As Chief Medical Officer, Tony is the key medical advisor to the Secretary and Minister of Health.
Prior to joining the Department in June 2023, Tony was Chief Medical Officer and Deputy Secretary– Clinical Quality, Regulation and Accreditation with the Tasmanian Department of Health. This role included providing leadership to health professionals, system-wide clinical governance oversight, and the regulation of private health service establishments.
Having studied medicine at the University of Tasmania, Tony has worked in the health system as a Specialist Emergency Physician, Specialist Medical Administrator, and senior health public servant for almost 30 years. During the COVID-19 pandemic, Tony was the Tasmanian Health Service Emergency Operations Commander.
Tony has previously held positions as a member of the Board of the Australian Commission on Safety and Quality in Health Care and the Council of the National Health and Medical Research Council, President of the Australasian College for Emergency Medicine, and Deputy Head of the Tasmanian School of Medicine.
Tony is a Professor in Health Services with the University of Tasmania.
Director, Regulatory and Industry Policy
James is a cyber security professional with a career spanning over 25 years specifically within the Australian Government context. James’ current role is the Director of Cyber Security Operations at the Australian Digital Health Agency. As a cyber security leader, James has extensive experience and expertise in providing policy and advice, compliance, assurance, security testing and operations, incident response, forensics, and capability development at operational and strategic levels. When not working, James can be seen out and about supporting community sports and charities.
Dalvin Chien is a Partner at Mills Oakley and a leading senior technology and data lawyer with over 20 years of experience. He has extensive experience in complex technology transactions, having acted for both vendors and purchasers of technology. Dalvin’s industry experience includes roles as senior legal counsel in various organizations, providing him with valuable insights into commercial and risk drivers. He has lead teams ranked in Legal 500 for Technology and has been a multi-year finalist for Cybersecurity Partner of the Year and Technology Law Partner of the Year at the LawyersWeekly Partner Awards. Dalvin is also an experienced director and frequently provides workshops and thought leadership on procurement, technology transformation, cybersecurity, innovation, data sharing, and Artificial Intelligence.
Paul Davies is Director for Government Affairs for Australia and New Zealand for Abbott, the major US diversified medical technology company. In this role he works across government, healthcare delivery and research arenas to develop and implement partnerships to advance Australian integration with Abbott’s core technologies in medical devices (particularly for diabetes, cardiovascular disease and brain and movement disorders), diagnostics at laboratory and point of care for infectious and chronic disease, and science-based nutrition. Prior to joining Abbott, for 12 years Paul was a Director with C & M International, a leading public policy consulting firm in Washington DC, representing clients in the consumer products, advanced materials, health, information technology and broadcasting sectors. Paul was a senior official in the Australian Department of Foreign Affairs and Trade where he represented the Australian Government in trade negotiations for over 12 years, including the U.S.-Australia Free Trade Agreement. Paul was trade policy adviser to the Australian Minister for Trade, Mark Vaile from 2000-2002.
Closing Remarks
Richard has more than 30 years experience in top-tier management consulting, new venture development, venture capital, and R&D engineering. With regards to startups and spinouts, he is both a professional adviser and an investor. He has been a VC fund investment director and IC member. His hobby is Sydney Angels, where he has led syndicates investing in medical device and biotech startups. Richard holds an MBA from London Business School and a first class honours degree in Mechanical Engineering from the University of Western Australia.
Gary Zamel is a serial entrepreneur with over 35 years of experience in investing in, scaling, and successfully exiting medical technology and other companies. With an extensive network across the research, product development, technology, commercial and managerial arenas, and strong connections with a broad pool of sophisticated investors, Gary is able to form cohesive teams to meet the differing timeline needs of bringing products to market. He is Founder and Director of New Medtek Devices P/L and Chairman of Medmine Partners P/L .
Michael joined Macquarie Group after completing bachelors of commerce and science at Melbourne University and spent 13 years as adviser, funds manager and project manager in Melbourne, Seoul, Moscow, Almaty, London and Manila. During this time, he advised Australian businesses on capital raising strategies, invested more than A$2 billion and led the investment activities for a A$1billion investment fund in Russia, established a start-up company in Kazakhstan and held an executive roles in a pre-revenue project in Philippines. After returning to Australia in 2016, Michael sought to combine his extensive strategic, commercial, financial, project and risk management expertise with his passion for the life science sector and has raised funds for, and represented investors as non-executive and executive director on a range of life science companies.
Rowena has over 15 years of experience in private equity, investing in growing businesses in Europe, US and Australia. Rowena is currently a Director at ARCHIMED, a global private equity fund specialised in healthcare with €8bn AUM, where she leads its development in Australia. Prior to this she worked in London as a Director at 3i, a FTSE 50 private equity investor, where she led investments across a range of sectors and scenarios. Passionate about working with diverse teams to deliver sustainable, purpose-led outcomes, Rowena has also volunteered for JDRF, the leading global type 1 diabetes research charity, and Ecole Saint Famille d’Urquijo in France. Now based in Sydney, Rowena is married with 3 children and is always looking forward to the next active adventure.
Dr Joseph Ischia is an accomplished and world-renowned Surgeon-Scientist Urologist with 15 years of clinical expertise in major open and robotic urological cancer surgery. He is an associate professor at the University of Melbourne with extensive experience and substantial success in leading research to ensure improved outcomes for patients with urological cancers. He completed a PhD at the University of Melbourne and did a two-year Uro-oncology fellowship at the Vancouver Prostate Centre. He currently supervises 1 PHD and 7 Masters of Surgery higher degree students at the University. Experience includes Chief Investigator and Listed Investigator roles on national and international research and clinical trials, invited plenary, guest and renowned speaker at premier urological scientific meetings worldwide, and membership of scientific organizing committees of both National and International urological meetings. He is a member of the internationally renowned Urological Research Society, American Urology Association, European Association of Urology, and the Société Internationale d’Urologie. He leads a research group at University of Melbourne on artificial intelligence in urology, transformational changes in ureteric stenting outside the operating room. He started on of the first global urological podcast in 2016, Talking Urology, and founded MedLitGo.com, a free online resource for doctors on the latest prostate cancer papers. He is the CEO and founder of Akeeko which has developed a ureteric stent insertion device which has the potential to transform the management of acute renal colic.
Nick is an experienced founder, executive and company director with over 20 years industry experience across health, lifesciences & medtech and professional services. Nick is currently Executive Chairman and Co-Founder of scaleup Med-Tech Eudaemon Technologies, Chairman of medical device quality assurance and testing business Enersol and Founder & Managing Partner at specialist health and medical research consulting firm Chrysalis Advisory. Nick holds an MBA, BSc (Psychology), BCom, is a graduate of the Australian Institute of Company Directors, a qualified and accredited Mediator, and is formerly COO at leading paediatric medical research institute Telethon Kids Institute and ex KPMG in UK, Europe and Australia.
Amy Yu is a co-founder and CTO at Ventora Medical, a medical device start-up with a mission to help premature babies breathe. Ventora Medical is developing an Airway Pressure Monitor for neonatal and infant patients on non-invasive respiratory support. Through the successful development and commercialisation of the Airway Pressure Monitor, Ventora aims to assist clinicians with their clinical decision making to enable proactive and tailored respiratory treatment.
Andrew, Founding Partner at SoHi Partners, is on a mission to revolutionize the MedTech and Deep Tech industries. With 20+ years of expertise in finance and technology, he’s dedicated to creating businesses that improve human life. SoHi Partners: bringing science to humanity.
From 5.30pm-7.00pm there will be some surprises in the Exhibition space. Enjoy drinks, canapes, and catching up with industry friends, together with some light entertainment.
Claire Hooper had a busy first few years in comedy, as a Raw Comedy national finalist in 2004, a coveted spot on the Melbourne Comedy Festival’s Comedy Zone in 2005, and a Best Newcomer Nomination in 2006.
For four years Claire shared a set with Paul McDermott and Mikey Robbins on the iconic comedy show Good News Week as a team captain.
Claire hosted 5 seasons The Great Australian Bake Off for Foxtel’s LifeStyle Channel alongside the seriously funny Mel Buttle, and has been seen on Channel Ten’s The Project , ABC’s The Weekly, Question Everything and Spicks & Specks, SBS’ Celebrity Letters & Numbers and Channel Ten’s Would I Lie To You?
Claire is an accomplished podcaster, with 3 seasons of ABC’s acclaimed show The Pineapple Project under her belt, plus her own podcast “I’m the Worst with Claire Hooper” where she delves into the darkest secrets of her comedy mates.
Claire is also a children’s book author, a comedy director and (though it’s unlikely to be relevant) a qualified garden designer.
Her latest stand up comedy show So Proud recently toured the country, and her Melbourne Comedy Festival season won her the Piece of Wood Award.
For four years Claire shared a set with Paul McDermott and Mikey Robbins on the iconic comedy show Good News Week as a team captain.
Claire hosted 5 seasons The Great Australian Bake Off for Foxtel’s LifeStyle Channel alongside the seriously funny Mel Buttle, and has been seen on Channel Ten’s The Project , ABC’s The Weekly, Question Everything and Spicks & Specks, SBS’ Celebrity Letters & Numbers and Channel Ten’s Would I Lie To You?
Claire is an accomplished podcaster, with 3 seasons of ABC’s acclaimed show The Pineapple Project under her belt, plus her own podcast “I’m the Worst with Claire Hooper” where she delves into the darkest secrets of her comedy mates.
Claire is also a children’s book author, a comedy director and (though it’s unlikely to be relevant) a qualified garden designer.
Her latest stand up comedy show So Proud recently toured the country, and her Melbourne Comedy Festival season won her the Piece of Wood Award.
Welcome
Warren Bingham is a prominent figure in the medical devices, biotechnology and digital health sectors, known for his leadership and innovative contributions. He is the Founder and Executive Chairman of MedTech International, Global Vice President of ARIA Research, Executive Chairman of OmnisOva, Chairman of Agscent, and MTAA Board member. With over 30 years of experience in the medical devices sector, Warren specializes in guiding organizations towards innovation and success, particularly in medical devices and biotechnologies, excelling in global strategic execution, commercialization, and board fulfillment. In addition to his professional endeavors, Warren is deeply committed to philanthropy and community engagement. He serves as an Ambassador for the Vinnies CEO Sleepout and Diabetes Australia, contributes as a member of the Springboard Enterprises LifeSciences Council, and coaches for the Cerebral Palsy Alliance’s Accelerator, Remarkable and Taronga HATCH accelerator. Warren actively participates in initiatives aimed at driving positive change and making a tangible difference in people’s lives. Among Warren’s notable contributions to the healthcare industry is his role in establishing the Australian subsidiary of Given Imaging Ltd in 2001. Under his leadership, Given Imaging pioneered PillCam® technology, revolutionizing the visualization of the GI tract with its ingestible pill-sized camera. Warren’s strategic initiatives also led to the successful inclusion of Capsule Endoscopy on Australia’s Medicare Benefits Scheme in 2004. During his tenure on the global management team from 2000, Given Imaging experienced exponential growth, evolving from a start-up to a multinational, publicly traded company with revenues surpassing $250 million by 2013. In February 2014, Covidien acquired Given Imaging for approximately $1 billion. Warren’s exceptional leadership and contributions have garnered widespread recognition over the years. He was a finalist in the 2016 Australian Institute of Management’s ‘Excellence in Leadership Awards’ and was acknowledged by AusBiotech in 2018 for his ‘Outstanding Contribution to AusMedtech’. In 2019, Warren was named an Adjunct Fellow at Macquarie University and received the prestigious Medical Technology Association of Australia (MTAA) Outstanding Achievement Award in 2021 for his remarkable contributions to industry development, patient outcomes, and leadership. Warren’s unwavering passion, dedication, and visionary leadership continue to inspire positive change, drive innovation, and leave a lasting impact on the world
Patient advocacy plays a critical role in shaping the future of healthcare. Our distinguished speakers will share personal stories, highlight successful advocacy initiatives, and explore strategies for amplifying patient voices. Join us to learn how empowered patients can drive positive change, improve healthcare outcomes, and foster a more patient-centered healthcare system.
With the growing awareness of the environmental damage and health risks of micro plastics, this panel session explores opportunities to reduce and reuse waste in the medical product sector – from alternative raw materials behind plastics to repurposing single use plastics devices.
Click here to access Dashboard of Environmental Regulatory for MedTech in APAC.
Click here to slides on Dashboard of Environmental Regulatory for MedTech in Australia.
With a career spanning over 25 years in healthcare, Jane has worked across Australia, New Zealand and China, and has worked in medical devices, consumables, OTC and pharmaceuticals with organisations such as 3M, Roche and Janssen-Cilag. To build her strategic and creative thinking, Jane spent four years in healthcare advertising, and also took the leap into the not-for-profit sector, as Executive Director for the peak body for community care and contract holder for the delivery of home care services for the Commonwealth and State Governments.
Jane is currently the Managing Director for Cardinal Health ANZ, and President of a not-for-profit childcare.
Join Kerry Wilson a gender equality advocate and change maker as we explore: What if the key to unlocking your company’s full potential lies in addressing gender disparities in the workplace? Join us as we explore the transformative power of applying a gender lens and the practical steps you can take to drive organisational excellence.
While Australia has made major strides integrating digital technology into healthcare, there are still a lot of potential gains for the Government to unlock. Industry and Government need to ask “Is digital technology genuinely helping to improve health care access and are the benefits making its way to patients? What measures are in place to justify its effectiveness of digital technology integration into healthcare? And is Government effectively harnessing the power of AI and Data?” Answering these questions from a Government and Industry perspective, this 45-minute session will discuss how we can better leverage digital technology in our healthcare system.
The Productivity Commissioner will discuss recent Productivity Commission reports: Advances in Managing Healthcare Productivity; and Leveraging Digital Tech in Healthcare.
Closing Remarks
Ian Burgess is the CEO of the Medical Technology Association of Australia. Ian is a long-term leader in the Australian healthcare space having previously held CEO positions at the Australian Dental Association, Ortho Group Pty Limited and Australian Orthopaedic Association Limited. Ian is also a member of the Australian Institute of Company Directors and a non-executive director of Red Nose Ltd and SIDS and Kids (ACT) Ltd.
